While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...

Senseonics (NYSE:SENS) announced today that it began the launch of its Eversense 365 sensor with the Sequel Med Tech twiist ...

Supermodels, singers, and diabetics are all wearing it. Jake Leach, Dexcom CEO, says these sensors are the future.

DexCom, Inc. (NASDAQ:DXCM) shareholders should be happy to see the share price up 12% in the last month. But that doesn't help the fact that the three year return is less impressive. In fact, the ...

When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...

DexCom beat expectations in the third quarter, and it raised its revenue guidance for the full year. Manufacturing issues are putting pressure on margins. For 2026, the company sees growth missing ...

Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after market close. Here’s what you need to know. DexCom beat analysts’ revenue expectations by 2.8% last quarter, ...